Pulmonary Pharmacology

Correct Answer

B — Epoprostenol

Rationale

Epoprostenol is classified as synthetic prostacyclin and is the prototypical prostacyclin analog for pulmonary arterial hypertension requiring continuous intravenous infusion through a permanent central venous catheter. Its extremely short half-life of approximately 2 to 3 minutes and chemical instability at room temperature make continuous intravenous delivery mandatory. Treprostinil is also a prostacyclin analog but has a longer half-life of approximately 4 hours and is available via subcutaneous, intravenous, inhaled, and oral routes. Selexipag is a non-prostanoid oral prostacyclin receptor agonist. Iloprost is a stable prostacyclin analog available by inhalation or intravenously.

Correct Answer

D — Treprostinil

Rationale

Treprostinil is classified as a prostacyclin analog with a half-life of approximately 4 hours, enabling the broadest range of administration routes among prostacyclin pathway agents: subcutaneous, intravenous, inhaled, and oral. This flexibility allows individualized therapy based on patient tolerance and clinical circumstances. Epoprostenol has a half-life of 2 to 3 minutes and requires continuous intravenous infusion only. Iloprost is available by inhalation and intravenously but not subcutaneously or orally. Selexipag is an oral-only non-prostanoid prostacyclin receptor agonist.

Correct Answer

A — Selexipag

Rationale

Selexipag is classified as an oral, non-prostanoid selective IP receptor agonist. Unlike prostacyclin analogs that structurally mimic prostacyclin and can bind multiple prostaglandin receptors, selexipag's active metabolite (produced by hydrolysis) has 37-fold selectivity for the IP receptor over other prostaglandin receptors, reducing off-target prostaglandin receptor-mediated adverse effects. The GRIPHON trial demonstrated that selexipag reduced the composite morbidity and mortality endpoint in pulmonary arterial hypertension patients on background therapy. Treprostinil, iloprost, and epoprostenol are all prostacyclin analogs rather than non-prostanoid receptor agonists.

Correct Answer

C — Bosentan

Rationale

Bosentan is classified as a dual endothelin A and B receptor antagonist and was the first oral agent approved for pulmonary arterial hypertension. It carries the most pronounced hepatotoxicity signal in the endothelin receptor antagonist class — elevated liver enzymes occur in approximately 10% of patients, and monthly liver function test monitoring is required. Bosentan is also a potent inducer of CYP3A4 and CYP2C9, reducing plasma concentrations of warfarin, statins, cyclosporine, and other CYP substrates. Ambrisentan is a selective endothelin A antagonist with substantially lower hepatotoxicity. Macitentan is a dual endothelin A and B antagonist with high tissue penetrance but is not a CYP inducer. Riociguat is a soluble guanylate cyclase stimulator, not an endothelin receptor antagonist.

Correct Answer

B — Ambrisentan

Rationale

Ambrisentan is classified as a selective endothelin A receptor antagonist. Endothelin A receptors on pulmonary arterial smooth muscle cells mediate vasoconstriction and proliferation — their blockade is therapeutically beneficial. Endothelin B receptors on pulmonary vascular endothelial cells mediate vasodilation through nitric oxide and prostacyclin release and facilitate endothelin clearance — their blockade is counterproductive. By selectively blocking endothelin A while sparing endothelin B, ambrisentan preserves these beneficial endothelin B-mediated effects. Ambrisentan also has a substantially lower hepatotoxicity rate than bosentan. Bosentan and macitentan are dual endothelin A and B antagonists. Sildenafil is a phosphodiesterase-5 inhibitor.

Correct Answer

A — Sildenafil

Rationale

Sildenafil is classified as a phosphodiesterase-5 inhibitor approved for pulmonary arterial hypertension, dosed three times daily. By preventing cyclic GMP degradation, it sustains and amplifies the vasodilatory nitric oxide signal in pulmonary arterial smooth muscle cells. The absolute contraindication to nitrates of any form applies to all phosphodiesterase-5 inhibitors: combining them with nitrates produces additive cyclic GMP elevation leading to potentially fatal systemic hypotension. Tadalafil is also a phosphodiesterase-5 inhibitor for pulmonary arterial hypertension but is dosed once daily. Riociguat is a soluble guanylate cyclase stimulator — a different mechanistic class in the same nitric oxide pathway — and also carries the nitrate absolute contraindication. Ambrisentan is an endothelin A receptor antagonist.

Correct Answer

D — Prostacyclin analogs bind Gs-coupled IP receptors, raising cyclic AMP, activating protein kinase A, and producing vasodilation and inhibition of smooth muscle cell proliferation

Rationale

Prostacyclin acts through IP receptors (prostacyclin receptors) on pulmonary arterial smooth muscle cells and platelets that couple to Gs proteins. Gs activation stimulates adenylyl cyclase, raising intracellular cyclic AMP, which activates protein kinase A to produce smooth muscle relaxation and vasodilation. Protein kinase A also inhibits smooth muscle cell proliferation, addressing the vascular remodeling component of pulmonary arterial hypertension. This is the same Gs-cyclic AMP-protein kinase A signaling axis that mediates bronchodilation in the airway via beta-2 adrenergic receptors. Prostacyclin analogs do not activate the Gq pathway, do not couple to Gi, and do not directly stimulate soluble guanylate cyclase — that mechanism belongs to riociguat.

Correct Answer

B — Epoprostenol has a half-life of approximately 2 to 3 minutes and chemical instability at room temperature; abrupt discontinuation causes severe rebound pulmonary hypertension that can be fatal

Rationale

Epoprostenol has an extremely short half-life of approximately 2 to 3 minutes, meaning the drug is cleared from the circulation within minutes of any interruption in delivery. This necessitates uninterrupted continuous intravenous infusion — any pump failure, line occlusion, or accidental disconnection causes plasma concentrations to fall rapidly to zero. The abrupt loss of prostacyclin-mediated vasodilation in a pulmonary vasculature already wholly dependent on this signaling produces severe rebound pulmonary hypertension that can precipitate right ventricular failure and death. Chemical instability at room temperature in many formulations adds an additional handling constraint requiring ice packs or specialized formulations. These combined delivery challenges — not tachyphylaxis or anatomical delivery requirements — are the basis for continuous infusion through a permanent central venous catheter.

Correct Answer

C — Hepatotoxicity requiring monthly liver function monitoring and teratogenicity requiring two reliable forms of contraception in women of childbearing potential

Rationale

Bosentan carries two class-defining safety concerns that apply with particular force to bosentan itself. Hepatotoxicity is a class-wide concern for all endothelin receptor antagonists, but bosentan has the most pronounced signal — elevated liver enzymes occur in approximately 10% of patients, requiring monthly liver function test monitoring throughout treatment. Teratogenicity is an absolute contraindication for all endothelin receptor antagonists based on major teratogenic effects seen in animal studies; two reliable forms of contraception are required for women of childbearing potential throughout treatment. Bosentan is additionally a potent CYP3A4 and CYP2C9 inducer that reduces plasma levels of warfarin, statins, and other substrates — but this is a drug interaction concern, not itself a primary safety warning in the same category as hepatotoxicity and teratogenicity.

Correct Answer

A — Sparing endothelin B receptors on pulmonary vascular endothelial cells preserves endothelin B-mediated vasodilation through nitric oxide and prostacyclin release, and maintains endothelin clearance from the circulation

Rationale

Endothelin-1 acts on two receptor subtypes with opposing effects in the pulmonary vasculature. Endothelin A receptors on smooth muscle cells mediate vasoconstriction and proliferation — blocking them is the therapeutic goal. Endothelin B receptors on endothelial cells mediate vasodilation by stimulating release of nitric oxide and prostacyclin, and also facilitate endothelin-1 clearance from the circulation. Blocking endothelin B receptors is counterproductive: it removes endothelial vasodilatory tone and allows circulating endothelin-1 to accumulate. By selectively blocking endothelin A and sparing endothelin B, ambrisentan preserves these beneficial endothelial effects. Despite this theoretical advantage, clinical trials have not demonstrated that ambrisentan produces superior outcomes compared with dual antagonists — the theoretical concern about endothelin B blockade has not translated into a clear clinical difference.

Correct Answer

D — Both drug classes elevate cyclic GMP — nitrates by donating nitric oxide to activate guanylate cyclase, phosphodiesterase-5 inhibitors by preventing cyclic GMP degradation — producing additive vasodilation and potentially fatal systemic hypotension

Rationale

The absolute contraindication between phosphodiesterase-5 inhibitors and nitrates arises from convergent mechanisms on the same signaling molecule. Organic nitrates are metabolized to nitric oxide, which activates soluble guanylate cyclase to produce cyclic GMP, causing smooth muscle relaxation and vasodilation. Phosphodiesterase-5 inhibitors prevent the degradation of cyclic GMP by phosphodiesterase-5, prolonging and amplifying whatever cyclic GMP signal is present. When both classes are used together, cyclic GMP accumulates to levels that produce profound, potentially fatal systemic hypotension. This interaction is not limited to sildenafil and tadalafil — riociguat, which directly stimulates guanylate cyclase, shares the same absolute nitrate contraindication, and riociguat and phosphodiesterase-5 inhibitors must never be combined with each other for the same reason.

Correct Answer

B — Riociguat directly stimulates soluble guanylate cyclase through two complementary mechanisms and is the only approved oral therapy for chronic thromboembolic pulmonary hypertension in patients not eligible for surgery

Rationale

Riociguat works upstream of phosphodiesterase-5 inhibitors by directly stimulating soluble guanylate cyclase through two complementary mechanisms: it sensitizes soluble guanylate cyclase to the low nitric oxide concentrations present in diseased pulmonary vasculature, and it directly stimulates the enzyme independent of nitric oxide — increasing cyclic GMP production even when endothelial nitric oxide is impaired. Its distinctive approved indication is chronic thromboembolic pulmonary hypertension in patients who are not surgical candidates for pulmonary endarterectomy — a form of pulmonary hypertension caused by organized thrombus obstructing the pulmonary arteries rather than primary vasculopathy. No phosphodiesterase-5 inhibitor, prostacyclin agent, or endothelin receptor antagonist shares this indication. Riociguat carries the same absolute nitrate contraindication as phosphodiesterase-5 inhibitors.

Correct Answer

C — AMBITION demonstrated that upfront combination therapy with ambrisentan plus tadalafil reduced the risk of clinical failure events by approximately 50% compared with either drug as monotherapy, establishing dual upfront therapy as the standard initial approach

Rationale

The AMBITION trial compared upfront combination therapy with ambrisentan plus tadalafil against either drug as monotherapy in treatment-naive patients with pulmonary arterial hypertension. The combination arm reduced the risk of the primary composite endpoint — clinical failure events including death, hospitalization, disease progression, and unsatisfactory long-term clinical response — by approximately 50% relative to pooled monotherapy. This finding drove a paradigm shift away from sequential add-on therapy toward upfront dual combination therapy for most newly diagnosed patients. The trial specifically studied ambrisentan plus tadalafil — an endothelin A receptor antagonist with a phosphodiesterase-5 inhibitor — and does not directly support other dual combinations, though the principle of early combination therapy has influenced guideline recommendations broadly.

Correct Answer

A — The goal is to achieve and maintain low-risk status using clinical parameters including WHO functional class, six-minute walk distance, brain natriuretic peptide, and hemodynamic measurements; patients at intermediate or high risk at any reassessment require treatment escalation

Rationale

The three-strata risk assessment in pulmonary arterial hypertension — low, intermediate, and high risk — is based on clinical parameters including World Health Organization functional class, six-minute walk distance, brain natriuretic peptide or N-terminal pro-brain natriuretic peptide, right atrial pressure, cardiac index, and mixed venous oxygen saturation. The treatment goal is to achieve and maintain low-risk status. Patients assessed as intermediate or high risk at any follow-up visit require treatment escalation — this treat-to-target approach prevents the error of accepting stable but suboptimal disease in a condition with relentlessly progressive underlying pathology. Reassessment every 3 to 6 months is recommended regardless of apparent symptom stability, because hemodynamic deterioration often precedes symptomatic decline in pulmonary arterial hypertension.

Correct Answer

C — Epoprostenol has a half-life of approximately 2 to 3 minutes; interruption of delivery causes plasma levels to fall to zero within minutes, producing severe rebound pulmonary hypertension and acute right ventricular failure

Rationale

Epoprostenol's half-life of approximately 2 to 3 minutes means that any interruption in continuous delivery causes plasma concentrations to approach zero within minutes. In a patient with severe pulmonary arterial hypertension whose pulmonary vascular resistance depends entirely on continuous prostacyclin-mediated vasodilation, the abrupt loss of this vasodilatory support produces severe rebound pulmonary hypertension. The right ventricle, already chronically pressure-overloaded and hypertrophied, cannot sustain adequate forward output against the acutely elevated pulmonary vascular resistance, leading to acute right ventricular failure with the hemodynamic profile seen here. This is the most feared complication of epoprostenol therapy and the clinical scenario that defines pump failure and catheter complications as life-threatening emergencies in this patient population.

Correct Answer

B — Both sildenafil and nitroglycerin elevate cyclic GMP through complementary mechanisms — sildenafil by preventing its degradation and nitroglycerin by donating nitric oxide to activate guanylate cyclase — producing additive vasodilation and potentially fatal hypotension

Rationale

The absolute contraindication between sildenafil and nitrates arises because both drugs elevate cyclic GMP through different but additive mechanisms. Nitroglycerin is converted to nitric oxide, which activates soluble guanylate cyclase to produce cyclic GMP. Sildenafil inhibits phosphodiesterase-5, the enzyme that degrades cyclic GMP, prolonging and amplifying the cyclic GMP signal. When both are present, cyclic GMP accumulates to levels producing profound systemic vasodilation and hypotension — potentially fatal. This contraindication applies to all nitrate forms including sublingual, transdermal, and isosorbide preparations. The patient's chest discomfort must be evaluated for pulmonary hypertension-related causes, and antianginal therapy must be selected from agents that do not involve the nitric oxide-cyclic GMP pathway.

Correct Answer

D — Epoprostenol's half-life of approximately 2 to 3 minutes means abrupt discontinuation removes prostacyclin support within minutes; selexipag requires dose titration over weeks to achieve therapeutic IP receptor activation, leaving a dangerous gap in vasodilatory coverage

Rationale

The hazard of an abrupt switch arises from the mismatch between epoprostenol's pharmacokinetics and selexipag's titration requirements. Epoprostenol clears from the circulation within minutes of stopping delivery due to its 2 to 3 minute half-life. Selexipag, an oral non-prostanoid IP receptor agonist, must be started at a low dose and titrated upward over several weeks to the maximum tolerated maintenance dose — it cannot immediately replicate the vasodilatory effect that epoprostenol was providing. Stopping epoprostenol before selexipag reaches therapeutic levels exposes the patient to the same rebound pulmonary hypertension risk as any abrupt epoprostenol interruption. The safe transition protocol requires up-titrating selexipag to an effective dose while simultaneously weaning epoprostenol gradually, so prostacyclin pathway vasodilation is maintained continuously throughout the switch.

Correct Answer

A — Riociguat directly stimulates soluble guanylate cyclase to produce cyclic GMP; nitroglycerin donates nitric oxide to activate the same enzyme — additive cyclic GMP elevation causes potentially fatal hypotension. The appropriate next step is cardiac evaluation to determine whether the chest symptoms represent a pulmonary hypertension-related cause, coronary disease, or both, before selecting non-nitrate management

Rationale

Riociguat stimulates soluble guanylate cyclase through two mechanisms: it sensitizes the enzyme to available nitric oxide and also activates it directly, independent of nitric oxide. The result is increased cyclic GMP production. Nitroglycerin works by releasing nitric oxide, which activates soluble guanylate cyclase through the same enzyme riociguat is already stimulating. Together, they produce additive cyclic GMP accumulation and potentially fatal systemic hypotension — the same class of interaction that makes all nitrates absolutely contraindicated with phosphodiesterase-5 inhibitors. Riociguat's label explicitly prohibits all nitrate forms and also prohibits combination with phosphodiesterase-5 inhibitors. The clinical challenge is that chest symptoms in a pulmonary arterial hypertension patient may reflect right ventricular ischemia, pulmonary vascular disease progression, or coincident coronary artery disease — all of which require evaluation before selecting an antianginal strategy that avoids the nitric oxide-cyclic GMP pathway entirely. Isosorbide dinitrate is still a nitrate and shares the same contraindication.